Navigation Links
A ray of hope in Angioplasty dilemma

A new technique to keeping heart arteries flowing easily after angioplasty shows fantastic success in early testing, visibly solving a major weakness of the common procedure.Doctors released the longest follow up with the new technique - the drug-coated stent. In testing on 30 patients over three years, they found it to be 100 percent effective, an accomplishment almost unheard of in medicine.//

More than 1 million Americans undergo angioplasty annually, and the new approach is likely to be used on most of them if these promising early results hold up in further testing. They could be on the market as early as next year.// During angioplasty, doctors fish tiny balloons through clogged heart arteries, then inflate them briefly to open up blood flow. Frequently, though, the arteries squeeze shut again. In recent years, doctors have often left behind tiny wire coils, called stents, to prop the arteries open.

However, about one-quarter of the time, the reopened artery closes off, a condition called restenosis. It usually occurs when fast-growth scar-like tissue fills the artery, and it must be fixed with a repeat angioplasty or a coronary bypass.

The solution to this dilemma appears to be a new kind of stent that is coated with medicines that gradually ooze into the artery. The drugs keep cells from growing. At least eight different varieties - coated with different growth-inhibiting medicines - are now in testing, and many more are under development. The first was Cordis Corp.'s stent coated with the immune suppressing drug rapamycin, tested on patients in Brazil and the Netherlands.

Dr. J. Eduardo Sousa of the Dante Pazzanese Institute of Cardiology in Sao Paulo presented two years of follow up with those 30 initial patients. While three of them have needed heart procedures for worsening disease in other parts of their hearts, all of the areas treated with the Cordis stents are flowing freely. Sousa projected an X-ray of o ne of the patient's hearts, showing a wide, obstruction-free artery. ``No lesion. No problem,'' he said. ``The artery is completely open after two years follow up.''

Dr. Jean Fajadet of Thoraxcenter in Rotterdam gave results with the same stent after seven months in 238 patients. Again, not a single stent clogged up, compared with restenosis in 26 percent of those getting ordinary stents.

Dr. Sidney Smith, chief medical officer of the American Heart Association, cautioned that large, careful studies must be finished comparing the new stents with the ordinary kind. Nevertheless, he said, ``these are very impressive and very encouraging results. When you see zero restenosis at one year, it's a breakthrough. It's almost too good to believe when you see zero.''

Especially encouraging, Smith said, is the fact they seem to work in unusually small arteries and in those of diabetic patients. Both are very prone to reclogging. Dr. Greg Stone of Lenox Hill Hospital in New York City said the first of these stents could be available in 2003. Results of at least three large studies, necessary to win Food and Drug Administration approval, are expected on rival products within the next year.


'"/>




Related medicine news :

1. Cholesterol Drug Helps After Angioplasty
2. Angioplasty Should be the Standard
3. The Success Rate Of Angioplasty In Female Patients Low
4. Angioplasty The Much Preferred Treatment Of Choice For Heart Attacks
5. Angioplasty death risk reduced by doubling drug dose
6. Angioplasty death risk reduced by doubling drug dose
7. Angioplasty plus stenting better than thrombolysis for elderly patients with AMI
8. Patients Fare Better With Doctors Who Do More Angioplasty Procedures
9. Researchers Begin Study To Find Out If Angioplasty Can Be Safely Done In Smaller Hospitals
10. Drug-Coated Stents Work Better In Diabetic Patients After Angioplasty
11. Togadiyas Condition Stable After Undergoing Angioplasty
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... ... Apple Rehab Shelton Lakes , which specializes in the delivery of ... part of a disaster drill on October 3rd. , Apple Rehab participated with the ... as well as the Connecticut Long Term Care Mutual Aid Plan (LTC-MAP). The ...
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of ... collection of specialty vendors and unique items from across the nation, this holiday-themed event ... wellness services offered by the VNA. The boutique will be open Saturday, November ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th ... Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, ... The fun run is geared towards children of all ages; it is a non-competitive, ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... viewers the lowdown on sciatica in a new episode of "Success Files," which ... current events and innovation and investigates each subject in-depth with passion and integrity. ...
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of ... Philippines. “The Journey: From the Mountains to the Mission Field” is the creation of ... taught all ages and currently teaches a class of ladies at her church, which ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... their devotion to personalized service, SMP Pharmacy Solutions announces their ... South Florida Business Journal,s 50 Fastest-Growing Companies, and listed for ... specialty pharmacy has found its niche.  To that end, the ... by SFBJ as the 2017 Power Leader in Health Care. ... award in October, Bardisa said of the three achievements, "It,s ...
(Date:9/25/2017)... , Sept. 25, 2017   Montrium ... Master File solutions, today—from the IQPC Trial Master ... , NL)—announced that EastHORN Clinical Services has ... clinical programs and TMF management. EastHORN, a leading ... eTMF platform to increase transparency to enable greater ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
Breaking Medicine Technology: